METABOLITES OF ARACHIDONIC ACID – DETERMINANTS OF PARENCHYMA-STROMA RELATIONS IN THE KIDNEYS IN HEALTH AND DISEASE

kidney, metabolites of arachidonic acid

1. Данн МДж (ред.). Почечная эндокринология. Медицина, М., 1987; 11-111

2. Campean V, Theilig F, Paliege A et al. Key enzymes for renal prostaglandin synthesis: site specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 2003; 285: F19-F32

3. Karnik AM, Bashir R, Khan FA. Renal involvement in the systemic inflammatory reaction syndrome. Renal Fail 1998; 20: 103-116

4. McGiff JC, Ferreri NR, Carroll MA. The eicosanoid factor: a determinant of individuality of nephron segment. J Physiol Pharmacol 2002; 53 (4): 525-532

5. Reinhold SW, Vitzthum H, Filbeck T et al. Gene expression of 5-, 12- and 15-lipoxygenases and leukotriene receptors along the rat nephron. Am J Physiol Renal Physiol 2005; 289 (6): F1138-F1143

6. Fitzpatrick FA, Soberman RJ. Regulates formation of eicosanoids. J Clin Invest 2001; 277: 1347-1351

7. Piro M, Giubilato G, Pinelli M. Endothelium and inflammation. Panminerva Med 2005; 47 (2): 75-80

8. Han WK, Sapirestein A, Hung CC et al. Cross-talk between cytosolic phospholipase A2 (cPLA2) alpha and secretory PLA2 (sPLA2) in hydregen peroxide-induced arachidonic acid release in murine mesangial cells. J Biol Chem 2003; 278 (26): 24153-42163

9. Nasrallah R, Landry A, Scholey JW et al. Characterisation of the prostaglandine synthesis in cultured mesangial cells. Prostaglandins Leukot Essent Fatty Acids 2004; 70 (5): 455-464

10. Kantarki A, Thomas EVD. Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 2003; 14 (1): 4-12

11. Natarajan R, Reddy MA. HETEs and EETs in renal glomerular and epithelial cell function. Curr Opin Pharmacol 2003; 3 (2): 198-203

12. Castrop H, Schweda F, Schumacher K et al. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 2001; 12: 867-874

13. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases – insights from animal model. Kidney Int 2005; 67 (2): 404-419

14. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition Brain Res Brain Res Rev 2005; 48 (2): 352-359

15. Vitzthum H, Abt I, Einhellig S. Gene expression of prostanoid forming enzymes along the rat nephron. Kidney Int 2002; 62: 1570-1581

16. Harris RC, Breyer MD. Physiological regulation of COX-2 in the kidney. Am J Renal Physiol 2001; 281: F1-F11

17. Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000; 11: 2387-2394

18. Schermann J. Cyclooxygenase-2 and macula densa control of renin secretion. Nephrol Dial Transplant 2001; 16: 1735-1738

19. Petry C, Fritz G, Pfeilschifter J. Inhibition of Rho modulates cytokine induced prostaglandin E2 formation in renal mesangial cells. Biochim Biophys Acta 2004; 1636 (2-3): 108-118

20. Favreau F, Petit-Рaris I, Hauet T. Cyclooxygenase 1-dependent production of F2-isoprostane and changes in redox status during warm renal ishemia-reperfusion. Free Radic Biol Med 2004; 36 (8): 1034-1042

21. Nasrallah R, Hebert RL. Prostacyclin signaling in the kidney: implications for health and desease. Am J Physiol Renal Physiol 2005; 289 (2): F235-246

22. Jansen BL, Stubbe J, Hansen PB. Localization of prostaglandin E2 receptors in the rat kidney Am J Physiol Renal Physiol 2001; 280: F1001-1009

23. Lemieux LI, Rahal SS, Kennedy CR. PGE2 reduces arachidonic acid release in murine podocytes: evidence for autocrine feedback loop. Am J Physiol Renal Physiol 2003; 284 (2): 302-309

24. Undurti ND. Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11 (5): R155-162

25. Masaru M, Rich KA, Ingram M et al. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension 2002; 39: 785-789

26. Weicher W, Paliege A, Provoost AP. Upregulation of juxtaglomerular NOS1 and COX-2 preceeds glomerulosklerosis in fown-hooded hypertensive rats. Am J Physiol Renal Physiol 2001; 280: 706-714

27. Asano K, Taniguchi S, Nakao A et al. Distribution of platelet activating protein receptor mRNA along the rat nephron segments. Biochem Biophys Res Commun 1996; 225 (2): 352-357

28. Chao W, Olson MS. Platelet-activating factor: receptor and signaling transduction. Biochem J 1993; 292: 617-629

29. Kester M, Thomas CP, Wang J. Platelet activating factor stimulates multiple signaling pathways in cultured rat mesangial cells. J Cell Physiol 1992; 153 (2): 244-255

30. Harris RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002; 89: 10-17

31. Castrop H, Vitzthum H, Schumacher K et al. Low tonicity mediates a downregulation of COX-1 expression in the rat renal papilla. J Am Soc Nephrol 2002; 13: 1136-1144

32. Fuson AL, Komlosi P, Unlap TM. Immunolocalization of a microsomal prostaglandin E synthase in rabbit kidney. Am J Physiol Renal Physiol 2003; 285: F558-F564

33. Nishimura K, Tsumagari H, Morioka A et al. Regulation of apoptosis through arachidonate cascade in mammalian cells. Appl Biochem Biotechnol 2002: 102-103 (1-6): 239-250

34. Alexander LD, Alagarsamy S. Cyclic stretch induced cPLA2 and ERK 1/2 signaling in rabbit proximal tubule. Kidney Int 2004; 65 (2): 551-558

35. Han HJ, Park SH, Lee YJ. Epidermal growth factor effects in primary cultured renal proximal tubule cells: involvement of cAMP, PKC and PLA2. Kidney Blood Press Res 2003; 26 (3): 155-164

36. Kaergel E, Muller DN, Honek H. P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. Hypertension 2002; 40: 273-279

37. Node K, Huo Y, Ruan X. Anti-inflammatory properties of cytochrome p450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-1279

38. Spector AA, Fang X, Snyder GD. Epoxyeicosatrienoic acids: metabolism and biochemical function. Prog Lipid Res 2004; 43 (1): 55-90

39. Caron N, Hajjam A, Decleves AE. Changes in renal hemodynamics induced by indomethacin in the rat involve cytochrome P450 arachidonic acid-dependent epoxygenases. Clin Exp Pharmacol Physiol 2004; 31 (10): 683-690

40. Stec DE, Flasch A, Roman RJ. Distribution of cytochrome P450 isoforms along the nephron in mice. Am J Physiol Renal Physiol 2003; 284 (1): F95-F102

41. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608

42. Oyekan AO. Differential effects of 20-HETE on intrarenal blood flow in the rat. J Pharmacol Exp Ther 2005; 313 (3): 1289-1295

43. Yu Z, Davis BB, Morriseau C et al. Vascular location of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 2004; 286 (4): F720-726

44. Alonso-Galicia M, Maier KG, Green AS. Role of 20-HETE in the renal actions of angiotensin II. Am J Physiol Renal Physiol 2002; 283 (1): R60-68

45. McCarthy ET, Sharma R, Sharma M. Protective effect of 20-HETE on glomerular protein permeability barrier. Kidney Int 2005; 67 (1): 152-163

46. Oyekan AO. Nitric oxide inhibits renal cytochrome P450-dependent epoxygenases in the rat. Clin Exp Pharmacol Physiol 2002; 29 (11): 990-995

47. Hoagland KM, Flasch AK, Roman RJ. Inhibition of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 2003; 42 (4): 669-673

48. Winokur TS, Morrison AR. Regional synthesis of monohydroxy eikosanoids by the kidney. J Biol Chem 1981; 256: 10221-10223

49. Henderson WR. The role of leukotrienes in inflammation. Ann Int Med 1994; 121 (9): 684-697

50. Абрамова ТВ. Нейтрофилы при гломерулонефрите Нефрология 2005; 9 (2): 9-16

51. Montero A, Uda S, Kelavkar U. Increased 5-lipoxygenase activating protein in immune-mediated experimental nephritis. J Nephrol 2003; 16 (5): 686-690

52. Brock TG. Regulating leukotriene synthesis: the role of nuclear 5-lipoxigenase. J Cell Biochem 2005; 126 (2): 138-142

53. Valdivielso JM, Montero A, Bard KF. Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats. J Nephrol 2003; 16 (1): 85-94

54. Daha MR, van Kooten C. Is proximal tubular cell a proinflammatory cell? Nephrol Dialys Transplant 2000; 15 [Suppl. 6]: 41-43

55. Patel NS, Cuzzocrea S, Chatterjee PK. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004; 66 (2): 220-227

56. Sener G, Kaabsakal L, Cetinel S. Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. Burns 2005; 31 (5): 587-596